Growth factors in diabetic complications

References

• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med.329(14), 977–986 (1993).
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet352(9131), 854–865 (1998).
   PubMed Web of Science ®Google Scholar
• Wong JML, Constantino M, Twigg SM, Yue DK. The metabolic syndrome in Type 2 diabetes is associated with gender, ethnicity and an increased prevalence of chronic end-organ complications. Diabetes Obes. Metab.(2006) (In Press).
   PubMedGoogle Scholar
• Kao Y, Donaghue KC, Chan A, Bennetts BH, Knight J, Silink M. Paraoxonase gene cluster is a genetic marker for early microvascular complications in Type 1 diabetes. Diabet. Med.19(3), 212–215 (2002).
   Google Scholar
• Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature414(6865), 813–820 (2001).
   PubMed Web of Science ®Google Scholar
• van Nieuwenhoven FA, Jensen LJ, Flyvbjerg A, Goldschmeding R. Imbalance of growth factor signalling in diabetic kidney disease: is connective tissue growth factor (CTGF, CCN2) the perfect intervention point? Nephrol. Dial. Transplant.20(1), 6–10 (2005).
   PubMed Web of Science ®Google Scholar
• Bennett SP, Griffiths GD, Schor AM, Leese GP, Schor SL. Growth factors in the treatment of diabetic foot ulcers. Br. J. Surg.90(2), 133–146 (2003).
   PubMed Web of Science ®Google Scholar
• Martin P. Wound healing – aiming for perfect skin regeneration. Science276(5309), 75–81 (1997).
   PubMed Web of Science ®Google Scholar
• Hovind P, Rossing P, Tarnow L, Parving HH. Smoking and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care26(3), 911–916 (2003).
   Google Scholar
• Yokoyama H, Okudaira M, Otani T et al. Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan. Kidney Int.58(1), 302–311 (2000).
   PubMed Web of Science ®Google Scholar
• Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr. Rev.25(6), 971–1010 (2004).
   PubMed Web of Science ®Google Scholar
• Flyvbjerg A. Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia43(10), 1205–1223 (2000).
   PubMed Web of Science ®Google Scholar
• Cooper ME, Gilbert RE, Epstein M. Pathophysiology of diabetic nephropathy. Metabolism47(12 Suppl. 1), 3–6 (1998).
   PubMed Web of Science ®Google Scholar
• Castellino P, Tuttle KR, DeFronzo RA. Diabetic nephropathy. Curr. Ther. Endocrinol. Metab.5, 426–436 (1994).
   PubMedGoogle Scholar
• Mauer SM. Structural-functional correlations of diabetic nephropathy. Kidney Int.45(2), 612–622 (1994).
   PubMed Web of Science ®Google Scholar
• Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC. Structural–functional relationships in diabetic nephropathy. J. Clin. Invest.74(4), 1143–1155 (1984).
   PubMed Web of Science ®Google Scholar
• Osterby R, Parving HH, Hommel E, Jorgensen HE, Lokkegaard H. Glomerular structure and function in diabetic nephropathy. Early to advanced stages. Diabetes39(9), 1057–1063. (1990).
   PubMed Web of Science ®Google Scholar
• Riser BL, Cortes P, Yee J. Modelling the effects of vascular stress in mesangial cells. Curr. Opin. Nephrol. Hypertens.9(1), 43–47 (2000).
   PubMedGoogle Scholar
• Murphy M, Godson C, Cannon S et al. Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J. Biol. Chem.274(9), 5830–5834. (1999).
   PubMed Web of Science ®Google Scholar
• Adler S. Structure-function relationships in diabetic nephropathy: lessons and limitations. Kidney Int. Suppl.60, S42–S45 (1997).
   Google Scholar
• Ayo SH, Radnik RA, Glass WF II et al. Increased extracellular matrix synthesis and mRNA in mesangial cells grown in high-glucose medium. Am. J. Physiol.260(2 Pt 2), F185–F191 (1991).
   PubMed Web of Science ®Google Scholar
• McLennan SV, Fisher EJ, Yue DK, Turtle JR. High glucose concentration causes a decrease in mesangium degradation. A factor in the pathogenesis of diabetic nephropathy. Diabetes43(8), 1041–1045 (1994).
   PubMedGoogle Scholar
• Reckelhoff JF, Tygart VL, Mitias MM, Walcott JL. STZ-induced diabetes results in decreased activity of glomerular cathepsin and metalloprotease in rats. Diabetes42(10), 1425–1432 (1993).
   PubMed Web of Science ®Google Scholar
• Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc. Natl Acad. Sci. USA89(24), 12043–12047 (1992).
   PubMed Web of Science ®Google Scholar
• Striker LJ, Striker GE. Administration of AGEs in vivo induces extracellular matrix gene expression. Nephrol. Dial. Transplant.11(Suppl. 5), 62–65 (1996).
   PubMedGoogle Scholar
• Tack I, Elliot SJ, Potier M, Rivera A, Striker GE, Striker LJ. Autocrine activation of the IGF-I signaling pathway in mesangial cells isolated from diabetic NOD mice. Diabetes51(1), 182–188 (2002).
   PubMedGoogle Scholar
• Oemar BS, Foellmer HG, Hodgdon-Anandant L, Rosenzweig SA. Regulation of insulin-like growth factor I receptors in diabetic mesangial cells. J. Biol. Chem.266(4), 2369–2373 (1991).
   PubMed Web of Science ®Google Scholar
• Flyvbjerg A, Bennett WF, Rasch R, Kopchick JJ, Scarlett JA. Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice. Diabetes48(2), 377–382 (1999).
   PubMed Web of Science ®Google Scholar
• Segev Y, Landau D, Marbach M, Shehadeh N, Flyvbjerg A, Phillip M. Renal hypertrophy in hyperglycemic non-obese diabetic mice is associated with persistent renal accumulation of insulin-like growth factor I. J. Am. Soc. Nephrol.8(3), 436–444 (1997).
   PubMed Web of Science ®Google Scholar
• Haylor J, Hickling H, El Eter E et al. JB3, an IGF-I receptor antagonist, inhibits early renal growth in diabetic and uninephrectomized rats. J. Am. Soc. Nephrol.11(11), 2027–2035 (2000).
   PubMed Web of Science ®Google Scholar
• Verrotti A, Cieri F, Petitti MT, Morgese G, Chiarelli F. Growth hormone and IGF-I in diabetic children with and without microalbuminuria. Diabetes Nutr. Metab.12(4), 271–276 (1999).
   PubMedGoogle Scholar
• Kim NH, Jung HH, Cha DR, Choi DS. Expression of vascular endothelial growth factor in response to high glucose in rat mesangial cells. J. Endocrinol.165(3), 617–624 (2000).
   PubMedGoogle Scholar
• Treins C, Giorgetti-Peraldi S, Murdaca J, Van Obberghen E. Regulation of vascular endothelial growth factor expression by advanced glycation end products. J. Biol. Chem.276(47), 43836–43841 (2001).
   PubMed Web of Science ®Google Scholar
• Pupilli C, Lasagni L, Romagnani P et al. Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells. J. Am. Soc. Nephrol.10(2), 245–255 (1999).
   PubMed Web of Science ®Google Scholar
• Saijonmaa O, Nyman T, Kosonen R, Fyhrquist F. Upregulation of angiotensin-converting enzyme by vascular endothelial growth factor. Am. J. Physiol. Heart Circ. Physiol.280(2), H885–H891 (2001).
   Google Scholar
• Senthil D, Choudhury GG, McLaurin C, Kasinath BS. Vascular endothelial growth factor induces protein synthesis in renal epithelial cells: a potential role in diabetic nephropathy. Kidney Int.64(2), 468–479 (2003).
   PubMedGoogle Scholar
• Cooper ME, Vranes D, Youssef S et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes48(11), 2229–2239 (1999).
   Google Scholar
• Hoshi S, Shu Y, Yoshida F et al. Podocyte injury promotes progressive nephropathy in zucker diabetic fatty rats. Lab. Invest.82(1), 25–35 (2002).
   PubMedGoogle Scholar
• de Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental Diabetes J. Am. Soc. Nephrol.12(5), 993–1000 (2001).
   PubMed Web of Science ®Google Scholar
• Shulman K, Rosen S, Tognazzi K, Manseau EJ, Brown LF. Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases. J. Am. Soc. Nephrol.7(5), 661–666 (1996).
   PubMed Web of Science ®Google Scholar
• Border WA, Ruoslahti E. Transforming growth factor-β in disease: the dark side of tissue repair. J. Clin. Invest.90(1), 1–7. (1992).
   PubMed Web of Science ®Google Scholar
• Nakamura T, Miller D, Ruoslahti E, Border WA. Production of extracellular matrix by glomerular epithelial cells is regulated by transforming growth factor-β 1. Kidney Int.41(5), 1213–1221 (1992).
   PubMed Web of Science ®Google Scholar
• Kumar V, Abbas AK, Fausto N, Robbins SL, Cotran RS. Robbins and Cotran Pathologic Basis of Disease. Elsevier Saunders, Philadelphia, PA, USA (2005).
   Google Scholar
• Wolf G. Growth factors and the development of diabetic nephropathy. Curr. Diab. Rep.3(6), 485–490 (2003).
   PubMedGoogle Scholar
• Chen S, Cohen MP, Ziyadeh FN. Amadori-glycated albumin in diabetic nephropathy: pathophysiologic connections. Kidney Int. Suppl.77, S40–S44. (2000).
   Google Scholar
• Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M. Advanced glycation end products inhibit de novo protein synthesis and induce TGF-β overexpression in proximal tubular cells. Kidney Int.63(2), 464–473 (2003).
   PubMed Web of Science ®Google Scholar
• Ziyadeh FN, Sharma K, Ericksen M, Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-β. J. Clin. Invest.93(2), 536–542 (1994).
   PubMed Web of Science ®Google Scholar
• Gilbert RE, Krum H, Wilkinson-Berka J, Kelly DJ. The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations. Diabet. Med.20(8), 607–621 (2003).
   PubMed Web of Science ®Google Scholar
• Hong SW, Isono M, Chen S, Iglesias-De La Cruz MC, Han DC, Ziyadeh FN. Increased glomerular and tubular expression of transforming growth factor-β1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse. Am. J. Pathol.158(5), 1653–1663 (2001).
   PubMed Web of Science ®Google Scholar
• Brosius FC III. Trophic factors and cytokines in early diabetic glomerulopathy. Exp. Diabesity Res.4(4), 225–233 (2003).
   PubMedGoogle Scholar
• Gilbert RE, Cox A, Wu LL et al. Expression of transforming growth factor-β1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition. Diabetes47(3), 414–422 (1998).
   PubMed Web of Science ®Google Scholar
• Iwano M, Kubo A, Nishino T et al. Quantification of glomerular TGF-β1 mRNA in patients with diabetes mellitus. Kidney Int.49(4), 1120–1126 (1996).
   PubMed Web of Science ®Google Scholar
• Sharma K, Ziyadeh FN, Alzahabi B et al. Increased renal production of transforming growth factor-β1 in patients with type II Diabetes Diabetes46(5), 854–859 (1997).
   PubMed Web of Science ®Google Scholar
• Sharma K, Jin Y, Guo J, Ziyadeh FN. Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes45(4), 522–530 (1996).
   PubMed Web of Science ®Google Scholar
• Han DC, Hoffman BB, Hong SW, Guo J, Ziyadeh FN. Therapy with antisense TGFβ-1 oligooxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice.Am. J. Physiol. Renal Physiol.278(4), F628–F634 (2000).
   Web of Science ®Google Scholar
• Hill C, Flyvbjerg A, Rasch R, Bak M, Logan A. Transforming growth factor-β2 antibody attenuates fibrosis in the experimental diabetic rat kidney. J. Endocrinol.170(3), 647–651 (2001).
   PubMedGoogle Scholar
• Ito Y, Aten J, Bende RJ et al. Expression of connective tissue growth factor in human renal fibrosis. Kidney Int.53(4), 853–861 (1998).
   PubMed Web of Science ®Google Scholar
• Twigg SM, Cooper ME. The time has come to target connective tissue growth factor in diabetic complications. Diabetologia47(6), 965–968 (2004).
   PubMed Web of Science ®Google Scholar
• Wahab NA, Weston BS, Roberts T, Mason RM. Connective tissue growth factor and regulation of the mesangial cell cycle: role in cellular hypertrophy. J. Am. Soc. Nephrol.13(10), 2437–2445 (2002).
   PubMedGoogle Scholar
• Riser BL, Denichilo M, Cortes P et al. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J. Am. Soc. Nephrol.11(1), 25–38 (2000).
   PubMed Web of Science ®Google Scholar
• McLennan SV, Wang XY, Moreno V, Yue DK, Twigg SM. Connective tissue growth factor mediates high glucose effects on matrix degradation through tissue inhibitor of matrix metalloproteinase type 1: implications for diabetic nephropathy. Endocrinology145(12), 5646–5655 (2004).
   PubMed Web of Science ®Google Scholar
• Twigg SM, Chen MM, Joly AH et al. Advanced glycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: a potential mechanism for expansion of extracellular matrix in diabetes mellitus. Endocrinology142(5), 1760–1769 (2001).
   PubMed Web of Science ®Google Scholar
• Twigg SM, Joly AH, Chen MM et al. Connective tissue growth factor/IGF-binding protein-related protein-2 is a mediator in the induction of fibronectin by advanced glycosylation end-products in human dermal fibroblasts. Endocrinology143(4), 1260–1269 (2002).
   PubMed Web of Science ®Google Scholar
• Twigg SM, Cao Z, McLennan SV et al. Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology.143(12), 4907–4915 (2002).
   PubMed Web of Science ®Google Scholar
• Ito Y, Goldschmeding R, Bende R et al. Kinetics of connective tissue growth factor expression during experimental proliferative glomerulonephritis. J. Am. Soc. Nephrol.12(3), 472–484 (2001).
   PubMed Web of Science ®Google Scholar
• Liu BC, Chen Q, Luo DD et al. Mechanisms of irbesartan in prevention of renal lesion in streptozotocin-induced diabetic rats. Acta Pharmacol. Sin.24(1), 67–73 (2003).
   PubMed Web of Science ®Google Scholar
• Andersen S, van Nieuwenhoven FA, Tarnow L et al. Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy. Kidney Int.67(6), 2325–2329 (2005).
   PubMed Web of Science ®Google Scholar
• Seppa H, Grotendorst G, Seppa S, Schiffmann E, Martin GR. Platelet-derived growth factor in chemotactic for fibroblasts. J. Cell Biol.92(2), 584–588 (1982).
   PubMed Web of Science ®Google Scholar
• Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev.79(4), 1283–1316 (1999).
   PubMed Web of Science ®Google Scholar
• Throckmorton DC, Brogden AP, Min B, Rasmussen H, Kashgarian M. PDGF and TGF-β mediate collagen production by mesangial cells exposed to advanced glycosylation end products. Kidney Int.48(1), 111–117 (1995).
   PubMedGoogle Scholar
• Kelly DJ, Gilbert RE, Cox AJ, Soulis T, Jerums G, Cooper ME. Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. J. Am. Soc. Nephrol.12(10), 2098–2107 (2001).
   PubMed Web of Science ®Google Scholar
• Langham RG, Kelly DJ, Maguire J, Dowling JP, Gilbert RE, Thomson NM. Over-expression of platelet-derived growth factor in human diabetic nephropathy. Nephrol. Dial. Transplant.18(7), 1392–1396 (2003).
   PubMed Web of Science ®Google Scholar
• Gilbert RE, Cox A, McNally PG et al. Increased epidermal growth factor in experimental diabetes related kidney growth in rats. Diabetologia40(7), 778–785 (1997).
   PubMed Web of Science ®Google Scholar
• Kelly DJ, Cox AJ, Tolcos M, Cooper ME, Wilkinson-Berka JL, Gilbert RE. Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats. Kidney Int.61(1), 31–39 (2002).
   PubMed Web of Science ®Google Scholar
• Wassef L, Kelly DJ, Gilbert RE. Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental Diabetes Kidney Int.66(5), 1805–1814 (2004).
   PubMed Web of Science ®Google Scholar
• Wetzler C, Kampfer H, Stallmeyer B, Pfeilschifter J, Frank S. Large and sustained induction of chemokines during impaired wound healing in the genetically diabetic mouse: prolonged persistence of neutrophils and macrophages during the late phase of repair. J. Invest. Dermatol.115(2), 245–253 (2000).
   PubMed Web of Science ®Google Scholar
• Pierce GF. Inflammation in nonhealing diabetic wounds: the space-time continuum does matter. Am. J. Pathol.159(2), 399–403 (2001).
   PubMed Web of Science ®Google Scholar
• Parks WC. Matrix metalloproteinases in repair. Wound Repair Regen.7(6), 423–432 (1999).
   PubMed Web of Science ®Google Scholar
• Philipp K, Riedel F, Sauerbier M, Hormann K, Germann G. Targeting TGF-β in human keratinocytes and its potential role in wound healing. Int. J. Mol. Med.14(4), 589–593 (2004).
   PubMed Web of Science ®Google Scholar
• Shah M, Revis D, Herrick S et al. Role of elevated plasma transforming growth factor-β1 levels in wound healing. Am. J. Pathol.154(4), 1115–1124 (1999).
   PubMed Web of Science ®Google Scholar
• Galiano RD, Tepper OM, Pelo CR et al. Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am. J. Pathol.164(6), 1935–1947 (2004).
   PubMed Web of Science ®Google Scholar
• Singer AJ, Clark RA. Cutaneous wound healing. N. Engl. J. Med.341(10), 738–746 (1999).
   PubMed Web of Science ®Google Scholar
• Kubota S, Kawata K, Yanagita T, Doi H, Kitoh T, Takigawa M. Abundant retention and release of connective tissue growth factor (CTGF/CCN2) by platelets. J. Biochem. (Tokyo)136(3), 279–282 (2004).
   PubMed Web of Science ®Google Scholar
• da Costa Pinto FA, Malucelli BE. Inflammatory infiltrate, VEGF and FGF-2 contents during corneal angiogenesis in STZ-diabetic rats. Angiogenesis5(1–2), 67–74 (2002).
   PubMedGoogle Scholar
• Brown RL, Breeden MP, Greenhalgh DG. PDGF and TGF-α act synergistically to improve wound healing in the genetically diabetic mouse. J. Surg. Res.56(6), 562–570 (1994).
   PubMed Web of Science ®Google Scholar
• Inkinen K, Wolff H, Lindroos P, Ahonen J. Connective tissue growth factor and its correlation to other growth factors in experimental granulation tissue. Connect Tissue Res.44(1), 19–29 (2003).
   Google Scholar
• Amery CM. Growth factors and the management of the diabetic foot. Diabet. Med.22(Suppl. 1), 12–14 (2005).
   PubMedGoogle Scholar
• Roberts AB, Sporn MB, Assoian RK et al. Transforming growth factor type β: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc. Natl Acad. Sci. USA83(12), 4167–4171 (1986).
   PubMed Web of Science ®Google Scholar
• Tredget EB, Demare J, Chandran G, Tredget EE, Yang L, Ghahary A. Transforming growth factor-β and its effect on reepithelialization of partial-thickness ear wounds in transgenic mice. Wound Repair Regen.13(1), 61–67 (2005).
   PubMedGoogle Scholar
• Igarashi A, Okochi H, Bradham DM, Grotendorst GR. Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol. Biol. Cell4(6), 637–645 (1993).
   PubMed Web of Science ®Google Scholar
• O’Kane S, Ferguson MW. Transforming growth factor βs and wound healing. Int. J. Biochem. Cell Biol.29(1), 63–78 (1997).
   PubMed Web of Science ®Google Scholar
• Cowin AJ, Hatzirodos N, Holding CA et al. Effect of healing on the expression of transforming growth factor β(s) and their receptors in chronic venous leg ulcers. J. Invest. Dermatol.117(5), 1282–1289 (2001).
   PubMed Web of Science ®Google Scholar
• Crowe MJ, Doetschman T, Greenhalgh DG. Delayed wound healing in immunodeficient TGF-β 1 knockout mice. J. Invest. Dermatol.115(1), 3–11 (2000).
   PubMed Web of Science ®Google Scholar
• Oemar BS, Luscher TF. Connective tissue growth factor. Friend or foe? Arterioscler. Thromb. Vasc. Biol.17(8), 1483–1489. (1997).
   PubMed Web of Science ®Google Scholar
• Leask A, Abraham DJ. The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. Biochem. Cell Biol.81(6), 355–363 (2003).
   PubMed Web of Science ®Google Scholar
• Blom IE, Goldschmeding R, Leask A. Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy? Matrix Biol.21(6), 473–482 (2002).
   PubMed Web of Science ®Google Scholar
• Abreu JG, Ketpura NI, Reversade B, De Robertis EM. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-β. Nat. Cell Biol.4(8), 599–604 (2002).
   PubMed Web of Science ®Google Scholar
• Inoki I, Shiomi T, Hashimoto G et al. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J.16(2), 219–221 (2002).
   Google Scholar
• Mutsaers SE, Bishop JE, McGrouther G, Laurent GJ. Mechanisms of tissue repair: from wound healing to fibrosis. Int. J. Biochem. Cell Biol.29(1), 5–17 (1997).
   PubMed Web of Science ®Google Scholar
• Medina A, Scott PG, Ghahary A, Tredget EE. Pathophysiology of chronic nonhealing wounds. J. Burn Care Rehabil.26(4), 306–319 (2005).
   PubMedGoogle Scholar
• Bauer EA, Cooper TW, Huang JS, Altman J, Deuel TF. Stimulation of in vitro human skin collagenase expression by platelet-derived growth factor. Proc. Natl Acad. Sci. USA82(12), 4132–4136 (1985).
   PubMed Web of Science ®Google Scholar
• Fu X, Shen Z, Guo Z, Zhang M, Sheng Z. Healing of chronic cutaneous wounds by topical treatment with basic fibroblast growth factor. Chin. Med. J. (Engl.).115(3), 331–335. (2002).
   PubMedGoogle Scholar
• Robson MC, Dubay DA, Wang X, Franz MG. Effect of cytokine growth factors on the prevention of acute wound failure. Wound Repair Regen.12(1), 38–43 (2004).
   PubMed Web of Science ®Google Scholar
• Mustoe TA, Pierce GF, Morishima C, Deuel TF. Growth factor-induced acceleration of tissue repair through direct and inductive activities in a rabbit dermal ulcer model. J. Clin. Invest.87(2), 694–703 (1991).
   PubMed Web of Science ®Google Scholar
• Nanney LB. Epidermal and dermal effects of epidermal growth factor during wound repair. J. Invest. Dermatol.94(5), 624–629 (1990).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nature Med.9(6), 669–676 (2003).
   PubMed Web of Science ®Google Scholar
• Carmeliet P. Angiogenesis in health and disease. Nat.Med.9(6), 653–660 (2003).
   PubMed Web of Science ®Google Scholar
• Duh E, Aiello LP. Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes48(10), 1899–1906 (1999).
   PubMed Web of Science ®Google Scholar
• Jain RK. Molecular regulation of vessel maturation. Nat. Med.9(6), 685–693 (2003).
   PubMed Web of Science ®Google Scholar
• Igarashi A, Nashiro K, Kikuchi K et al. Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. J. Invest. Dermatol.106(4), 729–733 (1996).
   PubMed Web of Science ®Google Scholar
• Shimo T, Nakanishi T, Kimura Y et al. Inhibition of endogenous expression of connective tissue growth factor by its antisense oligonucleotide and antisense RNA suppresses proliferation and migration of vascular endothelial cells. J. Biochem. (Tokyo)124(1), 130–140 (1998).
   PubMed Web of Science ®Google Scholar
• Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care26(6), 1790–1795 (2003).
   PubMed Web of Science ®Google Scholar
• Bucalo BEWFV. Inhibition of cell proliferation by chronic wound fluid. Wound Repair Regen.1, 181–186 (1993).
   PubMedGoogle Scholar
• Chesnoy S, Lee PY, Huang L. Intradermal injection of transforming growth factor-β1 gene enhances wound healing in genetically diabetic mice. Pharm. Res.20(3), 345–350 (2003).
   PubMed Web of Science ®Google Scholar
• Loots MA, Lamme EN, Zeegelaar J, Mekkes JR, Bos JD, Middelkoop E. Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. J. Invest. Dermatol.111(5), 850–857 (1998).
   PubMed Web of Science ®Google Scholar
• Ferguson MW, Herrick SE, Spencer MJ, Shaw JE, Boulton AJ, Sloan P. The histology of diabetic foot ulcers. Diabet. Med.13(Suppl. 1), S30–S33 (1996).
   PubMedGoogle Scholar
• Bitar MS, Labbad ZN. Transforming growth factor-β and insulin-like growth factor-I in relation to diabetes-induced impairment of wound healing. J. Surg. Res.61(1), 113–119 (1996).
   PubMed Web of Science ®Google Scholar
• Falanga V. Wound healing and its impairment in the diabetic foot. Lancet366(9498), 1736–1743 (2005).
   PubMed Web of Science ®Google Scholar
• Loots MA, Lamme EN, Mekkes JR, Bos JD, Middelkoop E. Cultured fibroblasts from chronic diabetic wounds on the lower extremity (non-insulin-dependent diabetes mellitus) show disturbed proliferation. Arch. Dermatol. Res.291(2–3), 93–99 (1999).
   PubMed Web of Science ®Google Scholar
• Signorelli SS, Malaponte G, Libra M et al. Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease. Vasc. Med.10(1), 1–6 (2005).
   PubMed Web of Science ®Google Scholar
• Jeffcoate WJ, Price P, Harding KG. Wound healing and treatments for people with diabetic foot ulcers. Diabetes Metab. Res. Rev.20(Suppl. 1), S78–S89 (2004).
   PubMed Web of Science ®Google Scholar
• Jeffcoate WJ, Harding KG. Diabetic foot ulcers. Lancet361(9368), 1545–1551 (2003).
   PubMed Web of Science ®Google Scholar
• Moulin V, Lawny F, Barritault D, Caruelle JP. Platelet releasate treatment improves skin healing in diabetic rats through endogenous growth factor secretion. Cell Mol. Biol. (Noisy-le-grand)44(6), 961–971 (1998).
   PubMedGoogle Scholar
• Lauer G, Sollberg S, Cole M et al. Expression and proteolysis of vascular endothelial growth factor is increased in chronic wounds. J. Invest. Dermatol.115(1), 12–18 (2000).
   PubMed Web of Science ®Google Scholar
• Michaels JT, Dobryansky M, Galiano RD et al. Topical vascular endothelial growth factor reverses delayed wound healing secondary to angiogenesis inhibitor administration. Wound Repair Regen.13(5), 506–512 (2005).
   PubMed Web of Science ®Google Scholar
• Richard JL, Parer-Richard C, Daures JP et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. A pilot, randomized, double-blind, placebo-controlled study. Diabetes Care18(1), 64–69 (1995).
   PubMed Web of Science ®Google Scholar
• Jude EB, Blakytny R, Bulmer J, Boulton AJ, Ferguson MW. Transforming growth factor-β 1, 2, 3 and receptor type I and II in diabetic foot ulcers. Diabet. Med.19(6), 440–447 (2002).
   PubMed Web of Science ®Google Scholar
• Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A Phase III randomized placebo-controlled double-blind study. Diabetes Care21(5), 822–827 (1998).
   PubMed Web of Science ®Google Scholar
• Eldor R, Raz I, Ben Yehuda A, Boulton AJ. New and experimental approaches to treatment of diabetic foot ulcers: a comprehensive review of emerging treatment strategies. Diabet. Med.21(11), 1161–1173 (2004).
   PubMed Web of Science ®Google Scholar
• Tsang MW, Wong WK, Hung CS et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care26(6), 1856–1861 (2003).
   PubMed Web of Science ®Google Scholar
• Brown RL, Breeden MP, Greenhalgh. PDGF and TGF-α act synergistically to improve wound healing in the genetically diabetic mouse. J. Surg. Research56, 562–570 (1994).
   PubMed Web of Science ®Google Scholar
• Eming SA, Krieg T, Davidson JM. Gene transfer in tissue repair: status, challenges and future directions. Expert Opin. Biol. Ther.4(9), 1373–1386 (2004).
   PubMed Web of Science ®Google Scholar
• Yonem A, Cakir B, Guler S, Azal OO, Corakci A. Effects of granulocyte-colony stimulating factor in the treatment of diabetic foot infection. Diabetes Obes. Metab.3(5), 332–337 (2001).
   PubMedGoogle Scholar
• Gough A, Clapperton M, Rolando N, Foster AV, Philpott-Howard J, Edmonds ME. Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection. Lancet350(9081), 855–859 (1997).
   PubMed Web of Science ®Google Scholar
• Lazareth I. [Local care and medical treatment for ischemic diabetic ulcers]. J. Mal. Vasc.27(3), 157–163 (2002).
   PubMedGoogle Scholar
• de Lalla F, Pellizzer G, Strazzabosco M et al. Randomized prospective controlled trial of recombinant granulocyte colony-stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection. Antimicrob. Agents Chemother.45(4), 1094–1098 (2001).
   PubMed Web of Science ®Google Scholar
• Aiello LP, Pierce EA, Foley ED et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl Acad. Sci. USA92(23), 10457–10461 (1995).
   PubMed Web of Science ®Google Scholar
• Wilkinson-Berka JL. Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cycoloxygenase-2 and nitric oxide. Curr. Pharm. Des.10(27), 3331–3348 (2004).
   PubMed Web of Science ®Google Scholar
• Letterio JJ, Bottinger EP. TGF-β knockout and dominant-negative receptor transgenic mice. Miner Electrolyte Metab.24(2–3), 161–167 (1998).
   PubMedGoogle Scholar
• Goss JR, Natsume A, Wolfe D, Mata M, Glorioso JC, Fink DJ. Delivery of herpes simplex virus-based vectors to the nervous system. Methods Mol. Biol.246, 309–322 (2004).
   PubMedGoogle Scholar
• Zhang W, Feng J, Li Y, Guo N, Shen B. Humanization of an anti-human TNF-α antibody by variable region resurfacing with the aid of molecular modeling. Mol. Immunol.42(12), 1445–1451 (2005).
   PubMedGoogle Scholar
• Zhou J, Neale JH, Pomper MG, Kozikowski AP. NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat. Rev. Drug Discov.4(12), 1015–1026 (2005).
   PubMed Web of Science ®Google Scholar
• Steed DL, Goslen JB, Holloway GA, Malone JM, Bunt TJ, Webster MW. Randomized prospective double-blind trial in healing chronic diabetic foot ulcers. CT-102 activated platelet supernatant, topical versus placebo. Diabetes Care15(11), 1598–1604 (1992).
   PubMed Web of Science ®Google Scholar
• Schratzberger P, Walter DH, Rittig K et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J. Clin. Invest.107(9), 1083–1092 (2001).
   PubMed Web of Science ®Google Scholar
• Yoon YS, Uchida S, Masuo O et al. Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation111(16), 2073–2085 (2005).
   PubMed Web of Science ®Google Scholar
• Ahmad FK, He Z, King GL. Molecular targets of diabetic cardiovascular complications. Curr. Drug Targets6(4), 487–494 (2005).
   PubMed Web of Science ®Google Scholar
• Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N. Engl. J. Med.339(2), 69–75 (1998).
   PubMed Web of Science ®Google Scholar
• Davis WA, Knuiman M, Kendall P, Grange V, Davis TM. Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care27(3), 752–757 (2004).
   PubMed Web of Science ®Google Scholar
• Lum C, Shesely EG, Potter DL, Beierwaltes WH. Cardiovascular and renal phenotype in mice with one or two renin genes. Hypertension43(1), 79–86 (2004).
   PubMedGoogle Scholar
• Marston WA, Hanft J, Norwood P, Pollak R. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care26(6), 1701–1705 (2003).
   PubMed Web of Science ®Google Scholar